Messenger RNA (mRNA) therapeutics have moved from a promising idea to clinical reality, accelerating vaccine development and ...

Researchers have developed a new lipid nanoparticle design that directs mRNA to the pancreas by exploiting the organ’s own ...

CD Bioparticles announces the launch of comprehensive Extrahepatic RNA Delivery services. NEW YORK, NY, UNITED STATES, ...

Lipid nanoparticles (LNPs) act as carriers for mRNA and CRISPR payloads across a wide range of therapeutic applications, from cancer to inflammatory and genetic diseases. The same delivery system used ...

Researchers are redesigning lipid nanoparticles to do more than shuttle mRNA into cells, with preclinical studies suggesting ...

The earliest iteration of LNPs was the development of liposomes in the 1960s, with the first liposome-based drug product, Doxil, receiving FDA approval in 1995. In the early 1990s, a second generation ...

Next-generation cell therapies are reshaping therapeutics by precisely engineering living cells for both ex vivo and in vivo applications. Cutting-edge tools—including Cas enzymes (Cas9, Cas12a), base ...